PCSK9 and diabetes mellitus: However, contradictory findings concerning the relationship between dyslipidemia and diabetes are also noted: Hyperlipidemic patients receiving lipid-lowering therapy with PCSK9 inhibitory antibodies or statins show an increased incidence of new-onset diabetes [18,19,20].